香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） 有關自願公告的補充公告 茲提述日期為2026年1月21日的自願公告（「該公告」）。除文義另有所指外，本 公告所用詞彙與該公告所界定者具有相同涵義。 董事會謹此提供進一步資料說明，防脫泡沫劑產品（「該產品」）為本公司化妝 品品牌KOSHINÉ旗下以KX-826為主要成分的產品之一。本公司謹此澄清，儘 管銷售代理協議為進一步推動本公司化妝品商業化提供了有利機會，但與本 集團的上市業務（即本公司核心產品KX-826及GT20029及其他管線產品的開發 及商業化）（「上市業務」）相比，該化妝品銷售業務目前規模較小，屬輔助性質。 謹此說明，該公告所披露的人民幣100百萬元銷售目標是按累計基準計量的長 期目標，而非預期於短期內達致 ...

Group 1 - The company reported an increase in revenue from RMB 0 million to RMB 6.0 million for the six months ending June 30, 2025, primarily driven by global sales of its new high-end cosmetics brand KOSHINé [1] - Research and development costs rose by RMB 9.3 million or 23.6% from RMB 39.3 million for the six months ending June 30, 2024, to RMB 48.6 million for the six months ending June 30, 2025, due to a focus on core dermatology pipelines KX-826 and GT20029 [1] - The company has five potential first-in-class/best-in-class drug candidates in clinical stages I-III and one new whitening ingredient KT-939, with significant progress in clinical trials for KX-826 and GT20029 in China [1] Group 2 - The company is in a transitional phase from research and development to commercialization of its cosmetics, planning to allocate more resources to explore various methods, including launching new products and increasing promotion in both domestic and overseas markets [2] - Future strategies include deepening partnerships with leading e-commerce platforms such as Tmall, JD.com, Douyin, Xiaohongshu, and Amazon, and establishing a diversified sales channel system [2] - The company aims to enhance customer resource expansion and loyalty through various promotional activities and refined membership management, including hosting exclusive member events and collaborating with selected KOLs and KOCs to accelerate online sales growth [2]